INTRODUCTION: Surveys state a widespread use of complementary and alternative medicine (CAM) in patients with malignant diseases. CAM methods might potentially interfere with the metabolization of tumor-specific therapy. However, there is little communication about CAM use in hematology/oncology patients between patients, CAM providers, and oncologists. PATIENTS AND METHODS: A self-administered questionnaire was handed out to all patients attending to the hematology/oncology outpatient clinic of Regensburg University Hospital. Subsequently, a chart review of all CAM users was performed. RESULTS: Questionnaires of 1,016 patients were analyzed. Of these patients, 30% used CAM, preferably vitamins and micronutrients. Main information sources for CAM methods were physicians/nonmedical practitioners and friends/relatives. CAM therapies were provided mainly by licensed physicians (29%), followed by nonmedical practitioners (14%) and the patients themselves (13%). Although 62% of the CAM users agreed that the oncologist may know about their CAM therapy, a chart entry about CAM use was found only in 41%. CONCLUSION: CAM is frequently used by hematology/oncology patients. Systematic communication about CAM is essential to avoid possible drug interactions.
INTRODUCTION: Surveys state a widespread use of complementary and alternative medicine (CAM) in patients with malignant diseases. CAM methods might potentially interfere with the metabolization of tumor-specific therapy. However, there is little communication about CAM use in hematology/oncology patients between patients, CAM providers, and oncologists. PATIENTS AND METHODS: A self-administered questionnaire was handed out to all patients attending to the hematology/oncology outpatient clinic of Regensburg University Hospital. Subsequently, a chart review of all CAM users was performed. RESULTS: Questionnaires of 1,016 patients were analyzed. Of these patients, 30% used CAM, preferably vitamins and micronutrients. Main information sources for CAM methods were physicians/nonmedical practitioners and friends/relatives. CAM therapies were provided mainly by licensed physicians (29%), followed by nonmedical practitioners (14%) and the patients themselves (13%). Although 62% of the CAM users agreed that the oncologist may know about their CAM therapy, a chart entry about CAM use was found only in 41%. CONCLUSION: CAM is frequently used by hematology/oncology patients. Systematic communication about CAM is essential to avoid possible drug interactions.
Authors: Ann-Kathrin Lederer; Alexandra Baginski; Lena Raab; Stefanie Joos; Jan Valentini; Carina Klocke; Yvonne Samstag; Katrin Hübner; Ivana Andreeva; Thomas Simmet; Tatiana Syrovets; Susanne Hafner; Anna Freisinger; Maximilian Andreas Storz; Roman Huber Journal: BMC Complement Med Ther Date: 2021-11-23
Authors: Olesya Vakhrusheva; Holger H H Erb; Vitus Bräunig; Sascha D Markowitsch; Patricia Schupp; Patrick C Baer; Kimberly Sue Slade; Anita Thomas; Igor Tsaur; Martin Puhr; Zoran Culig; Jindrich Cinatl; Martin Michaelis; Thomas Efferth; Axel Haferkamp; Eva Juengel Journal: Front Oncol Date: 2022-02-07 Impact factor: 6.244
Authors: Markus Horneber; Gerd van Ackeren; Felix Fischer; Herbert Kappauf; Josef Birkmann Journal: Integr Cancer Ther Date: 2018-10-23 Impact factor: 3.279